Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Medicines licensing

FDA grants priority approval for new antifungal

Isavuconazonium sulfate (Cresemba), an antifungal developed by Astellas, has been given priority approval by the US Food and Drug Administration (FDA) to treat patients with the rare but serious infections invasive aspergillosis and invasive mucormycosis.

The drug is the sixth to be awarded qualified infectious disease product (QIDP) status, which means it was given priority review by the medicines regulator because of its potential to treat serious infections.

It has also been recognised as an orphan drug by the FDA for the two conditions and, because of its QIDP status, was given an additional five years of marketing exclusivity.

The decision to approve the drug for invasive aspergillosis was based on clinical trial results for 516 patients that compared isavuconazonium with voriconazole. All-cause mortality at six weeks was 18.6% in the isavuconazonium group and 20.2% in the voriconazole group, according to Astellas.

The drug’s approval for invasive mucormycosis was based on data from a trial of 37 patients that compared isavuconazonium treatment against the natural progression of the disease, in patients who were left untreated. All-cause mortality for isavuconazonium patients was 38%, according to Astellas.

A spokesperson for the company says it will launch Cresemba in the United States “in the coming months”.

Basilea Medical has the rights to market the product in the European Union and submitted an application for marketing authorisation to the European Medicines Agency in July 2014. The company expects the drug to be made available for the treatment of invasive aspergillosis and mucormycosis by the end of 2015.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068109

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Foundation in Pharmacy Practice

    Foundation in Pharmacy Practice

    A practical and succinct overview of the principal pharmacy practice topics, for new pharmacy students.

    £33.00Buy now
  • Non-medical Prescribing

    Non-medical Prescribing

    An essential new guide designed to ensure confident prescribing in specialist areas.

    £27.00Buy now
  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.